p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time

British Journal of Cancer

Volumn 69, Issue 2, 1994, Pages 337-341

  Piris, M A ^a   Pezzella, F ^b   Martinez Montero, J C ^a   Orradre, J L ^a   Villuendas, R ^a   Sanchez Beato, M ^a   Cuena, R ^a   Cruz, M A ^a   Martinez, B ^a   Garrido, M C ^b   Gatter, K ^b   Aiello, A ^c   Delia, D ^c   Giardini, R ^c   Rilke, F ^c  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; GENE EXPRESSION; HISTOLOGY; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; ITALY; LIFE EXPECTANCY; LYMPH NODE; LYMPHOMA; MAJOR CLINICAL STUDY; MUCOSA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SPAIN; SURVIVAL RATE; SURVIVAL TIME; TUMOR LOCALIZATION; UNITED KINGDOM;

HUMAN; LYMPHOMA, B-CELL; PROGNOSIS; PROTEIN P53; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS;

EID: 0028117150     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1994.61     Document Type: Article

References (45)

1. AISENBERG, AC., WILKES, B.M. & JACOBSON, J.O. (1988). The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood, 71, 969–972.
2. BANKS, S.J., MATLASHEWISKI, G. & CRAWFORD, L. (1986). Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem., 159, 529–534.
3. CABANILLAS, F., PATHAK, S., GRANT, G., HAGEMEISTER, F.B., MCLAUGHLIN, P., SWAN, F., RODRIGUEZ, M.A., TRUJILLO, J., CORK, A., BUTLER, J.J., KATZ, R., BOURNE, S. & FREIREICH, E.J. (1989). Refractoriness to chemotherapy and poor survival related to abnormalities of chromosome 17 and 7 in lymphoma. Am. J. Med., 87, 167–172.
4. CESERMAN, E., CHADBURN, A., INGHIRAMI, G., GAIDANO, G. & KNOWLES, D. (1992). Structural and functional analysis of oncogenes and tumour suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood, 80, 3205–3216.
5. CHIN, K.V., UEDA, K., PASTAN, I. & GOTTESMAN, M.M. (1992). Modulation of activity of the promotor of the human MDR1 gene by Ras and p53. Science, 255, 459–462.
6. CLARKE, A.R., PURDIE, C.A., HARRISON, D.J., MORRIS, R.G., BIRD, C.C., HOOPER, M L. & WYLLIE, A.H. (1993). Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature, 362, 849–852.
7. COIFFIER, B., GISSELBRECHT, C., VOSE, J.M., TILLY, H., HERBRECHT, R., BOSLY, A. & ARMITAGE, J.O. (1991). For the groupe d’Etudes des Lymphomes agressifs. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J. Clin. Oncol., 9, 211–219.
8. CORDELL, J.L., FALINI, B., ERBER, W.N., ABDULAZIZ, Z., MACDONALD, S., PULFORD, K.A.F., STEIN, H. & MASON, D.Y. (1984). Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal antialkaline phosphatase (APAAP complex). J. Histochem. Cytochem., 32, 219–222.
9. COX, D.R. (1972). Regression models and life tables. J. R. Stat. Soc., 34, 187–220.
10. DOGLIONI, C., PELOSIO, P., MOMBELLO, A., SCARPA, A. & CHILOSI, M. (1991). Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin’s disease and CD30 + anaplastic lymphomas. Hematol. Pathol., 5, 67–73.
11. FANIDI, A., HARRINGTON, E.A. & EVAN, G.I. (1992). Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature, 359, 554–556.
12. FARRELL, P.J., ALLAN, G.J., SHANAHAN, F., VOUSDEN, K.H. & CROOK, T. (1991). p53 is frequently mutated in Burkitt’s lymphoma cell lines. EM BO J., 10, 2879–2887.
13. FEARON, E.R. & VOGELSTEIN, B. (1990). A genetic model for colorectal tumorigenesis. Cell, 61, 759–767.
14. FINKE, J., FRITZEN, R., TERNES, P., TRIVEDI, P., BROSS, K.J., LANGE, W., MERTELSMANN, R. & DOLKEN, G. (1992). Expression of bcl-2 in Burkitt’s lymphoma cell lines: induction by latent Epstein-Barr virus genes. Blood, 80, 459–469.
15. FINLAY, C.A., HINDS, P.W., TAN, T.H., ALIYAHU, D., OREN, M. & LEVIN, J. (1988). Activating mutations for transformation by p53 produce a gene produce that forms hsc70-p53 complex with an altered half life. Mol. Cell. Biol, 8, 531–539.
16. FRITSCHE, M., HAESSLER, C. & BRANDNER, G. (1993). Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene, 8, 307–318.
17. GAIDANO, G., BALLERINI, P., GONG, J.Z., INGHIRAMI, G., NERI, A., NEWCOMB, E.W., MAGRATH, I.T., KNOWLES, D M. & DALLAFAVERA, R. (1991). p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 88, 5413.
18. HALL, P.A., MCKEE, P H., MENAGE, H P., DOVER, R. & LANE, D P. (1993). High levels of p53 in UV-irradiated normal human skin. Oncogene, 8, 203–207.
19. HENDERSON, S., ROWE, M., GREGORY, C., CROOM-CARTER, D., WANG, F., LONGNECKER, R., KIEFF, E. & KICKINSON, A. (1991). Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell, 65, 1107–1115.
20. HINDS, P.W., FINLAY, C.A., LEVINE, A.J. (1989). Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol., 63, 739–746.
21. HOCKENBERRY, D., NUNEZ, G., MILLIMAN, C., SCHEREIBER, R.D. & KORSMEYER, S.J. (1990). bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348, 334–336.
22. ICHIKAWA, A., HOTTA, T., TSUSHITA, K., KINOSHITA, T., NAGAI, H., MURAKAMI, Y., HAYASHI, K. & SAITO, H. (1992). Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood, 79, 2701–2707.
23. KAPLAN, E.L. & MEIER, P. (1958). Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457–481.
24. LANE, D., BENCHIMOL, S. (1990). Oncogene or anti-oncogene? Genes Dev., 4, 1–3.
25. LENNERT, K. & FELLER, A.C. (1990). Non-Hodgkin-Lymphome (nach der aktualisierten Kiel-Klassifikation). Springer: Berlin.
26. LEVINE, E.G., ARTHUR, DC., FRIZZERA, G., PETERSON, B.A., HURD, D.D. & BLOOMFIELD, C.D. (1988). Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphoma. Ann. Intern. Med., 108, 14–20.
27. LOWE, S.W., SCHMITT, E.M., SMITH, S.W., OSBORNE, B.A. & JACKS, T. (1993). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 362, 847–849.
28. MILNER, J. & MEDCALF, E.A. (1991). Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell, 65, 765–174.
29. PETO, R., ROE, F.J.C., LEE, P.N., LEVY, L. & CLACK, J. (1975). Cancer and ageing in mice and men. Br. J. Cancer, 32, 411–426.
30. PEZZELLA, F., TSE, A.G.D., CORDELL, J.L., PULFORD, K.A.F., GATTER, K.C. & MASON, D.Y. (1990). Expression of the bcl-2 oncogene protein is not specific for the 14; 18 chromosomal translocation. Am. J. Pathol., 137, 225–232.
31. PEZZELLA, F., JONES, M., RALFKIAER, E., ERSBOLL, J., GATTER, K.C. & MASON, D.Y. (1992). Evaluation of bcl-2 protein expression and 14; 18 translocation prognostic markers in follicular lymphoma. Br. J. Cancer, 65, 87–89.
32. PEZZELLA, F., MORRISON, H., JONES, M., GATTER, K.C., LANE, D., HARRIS, A.L. & MASON, D.Y. (1993). Immunohistochemical detection of p53 and bcl-2 protein in non-Hodgkin’s lymphoma. Histopathology, 22, 39–44.
33. RAGHOEBIER, S., KRAMER, M.H.H., VAN KRIEKEN, J.H.J.M., DE JONG, D., LIMPENS, J., KLUIN-NELEMANS, J.C., VAN OMMEN, G.J.B. & KLUIN, Ph. M. (1991). Essential differences in oncogene involvement between primary nodal and extranodal large cell lymphoma. Blood, 78, 2680–2685.
34. RODRIGUEZ, M.A., FORD, R.J., GOODACRE, A., SELVANAYAGAM, P., CABANILLAS, F. & DEISSEROTH, A.B. (1991). Chromsome 17p and p53 changes in lymphoma. Br. J. Haematol., 79, 575–582.
35. SCHOUTEN, H.C., SANGER, W.G., WEISENBURGER, D.D., ANDERSON, J. & ARMITAGE, J.O. (1990). Chromosomal abnormalities in untreated patients with non-Hodgkin’s lymphoma: associations with histology, clinical characteristics, and treatment outcome. Blood, 75, 1841–1847.
36. SETO, M., JAEGER, U., HOCKETT, R.D., GRANINGER, W., BENNETT, S., GOLDMAN, P. & KORSMEYER, S.J. (1988). Alternative promoters and exons, somatic mutation and deregulation of the bcl-2-Ig fusion gene in lymphoma. EMBO J., 7, 123–131.
37. SIDRANSKY, D., MIKKELSEN, T., SCHWECHHEIMER, K., ROSENBLUM, M L., CAVANEE, W. & VOGELSTEIN, B. (1992). Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature, 355, 846–847.
38. THOR, A.D., MOORE, D.H., EDGERTON, S.M., KAWAASAKI, E.S., REIHSAUS, E., LYNCH, H.T., MARCUS, J.N., SCHWARTZ, L., CHEN, L.L., MAYALL, B.H. & SMITH, H.S. (1992). Accumulation of p53 tumour suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl Cancer Inst., 84, 845–855.
39. VELASQUEZ, W.S., JAGANNATH, S., TUCKER, S.L., FULLER, L.M., NORTH, L.B., REDMAN, J R., SWAN, F., HAGEMEISTER, F.B., MCLAUGHLIN, P. & CABANILLAS, F. (1989). Risk classification as the basis for clinical staging of diffuse large cell lymphoma derived from 10-year survival data. Blood, 74, 551–557.
40. VILLUENDAS, R., PIRIS, M.A., ORRADRE, J.L., MOLLEJO, M., RODRIGUEZ, R. & MORENTE, M. (1991). Different bcl-2 protein expression in high-grade B-cell lymphomas derived from lymph node or mucosa-associated lymphoid tissue. Am. J. Pathol., 139, 989–993.
41. VILLUENDAS, R., PIRIS, M.A., ORRADRE, J.L., MOLLEJO, M., ALGARA, P., SANCHEZ, L., MARTINEZ, J.C. & MARTINEZ, P. (1992). p53 protein expression in lymphomas and reactive lymphoid tissue. J. Pathol., 166, 235–241.
42. VISAKORPI, T., KALLIONEMI, O.P., HEIKKINEN, A., KOIVULA, T. & ISOLA, J. (1992). Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl Cancer Inst., 84, 883–887.
43. WIMAN, K.G., MAGNUSSON, K.P., RAMQUIST, T. & KLEIN, G. (1991). Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. Oncogene, 6, 1633–1639.
44. YUNIS, J.J., MAYER, M.G., ARNESEN, M.A., AEPPLI, D.P., OKEN, M.M. & FRIZZERA, G. (1989). bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N. Engl. J. Med., 320, 1047–1054.
45. ZUTTER, M., HOCKENBERRY, D., SILVERMAN, G.A. & KORSMEYER, S.J. (1991). Immunolocalization of the bcl-2 protein within haematopoietic neoplasms. Blood, 78, 1062–1068.